Cue Biopharma vs Foghorn Therapeutics
Cue Biopharma and Foghorn Therapeutics are similar in size: $27.5m and $30.9m of revenue in their latest fiscal years. Cue Biopharma grew faster (195.7% against 36.8%). Cue Biopharma kept more of each dollar of sales as profit: a net margin of -96.9% against -240.3%.
| Latest fiscal year | Cue BiopharmaCUE, 2025 | Foghorn TherapeuticsFHTX, 2025 |
|---|---|---|
| Revenue | $27.5m | $30.9m |
| Revenue growth | 195.7% | 36.8% |
| Net income | −$26.6m | −$74.3m |
| Operating margin | — | -279.5% |
| Net margin | -96.9% | -240.3% |
| Return on equity | -121.1% | — |
| Free cash flow | −$21.9m | −$86.1m |
| Cash | $27.1m | $80.9m |
| Total debt | — | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 29 | 106 |
| Market value | $106m | $124m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 5 buys, 15 sales | 0 buys, 0 sales |